Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1970972-74-7
2. Danicamtiv [inn]
3. Danicamtiv [usan]
4. Myk-491
5. Sar440181
6. 7b2cs922hi
7. Myk491
8. Sar-440181
9. 1-piperidinecarboxamide, 4-((1r)-1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-3-isoxazolyl-
10. 4-[(1r)-1-[3-(difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-n-(1,2-oxazol-3-yl)piperidine-1-carboxamide
11. Danicamtiv (usan/inn)
12. Danicamtiv (myk-491)
13. Unii-7b2cs922hi
14. Chembl4594304
15. Schembl17942536
16. Ex-a5015
17. S9948
18. Who 10942
19. Sar 440181;myk-491
20. Hy-109128
21. Cs-0086762
22. D11824
23. (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
24. 4-((1r)-1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(1,2-oxazol-3-yl)piperidine-1-carboxamide
| Molecular Weight | 435.4 g/mol |
|---|---|
| Molecular Formula | C16H20F3N5O4S |
| XLogP3 | 1.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 435.11880980 g/mol |
| Monoisotopic Mass | 435.11880980 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 701 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Danicamtiv manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Danicamtiv, including repackagers and relabelers. The FDA regulates Danicamtiv manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Danicamtiv API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Danicamtiv supplier is an individual or a company that provides Danicamtiv active pharmaceutical ingredient (API) or Danicamtiv finished formulations upon request. The Danicamtiv suppliers may include Danicamtiv API manufacturers, exporters, distributors and traders.
Danicamtiv Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Danicamtiv GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Danicamtiv GMP manufacturer or Danicamtiv GMP API supplier for your needs.
A Danicamtiv CoA (Certificate of Analysis) is a formal document that attests to Danicamtiv's compliance with Danicamtiv specifications and serves as a tool for batch-level quality control.
Danicamtiv CoA mostly includes findings from lab analyses of a specific batch. For each Danicamtiv CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Danicamtiv may be tested according to a variety of international standards, such as European Pharmacopoeia (Danicamtiv EP), Danicamtiv JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Danicamtiv USP).
LOOKING FOR A SUPPLIER?
